An observational study in Prostate Carcinoma, Localized Prostate Adenocarcinoma and Stereotactic Body Radiotherapy, sponsored by University of Zurich. Active, not recruiting at 1 site in Switzerland. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Zurich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Prostatic Neoplasms with a site in Switzerland — 40 open to participants now, 58 under way, 20 of them phase 3. Prostatic Neoplasms · Switzerland.
Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, this one is the 25th largest by planned enrollment of the 28 observational ones that give a count, is one of 10 that started in 2024, is one of 28 observational ones, reaches primary completion later than 16 of the 57 other live ones, and was the 115th registered.
7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →40 of the 136 studies in Prostatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Men only
AstraZeneca · Sites in Switzerland, United States, Austria and 18 more countries
Ages 18+ · Men only
Massimo Valerio · Sites in Switzerland
Ages 18+ · Men only
University of Zurich · Sites in Switzerland
Ages 18+ · Men only
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 50+ · Men only · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 31 · Phase 3 43 · Phase 4 3
First in 1992; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 140 across the 107 interventional studies, 219 across the 28 observational. Of the 71 that completed or were terminated, 16 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 136 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
University of Zurich has 9 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Prostatic Neoplasms with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT07455097Heinrich-Heine University, DuesseldorfCOMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) | 2026-12-31 |
| NCT05850182Oncology Institute of Southern SwitzerlandLifestyle Intervention in Patients With Metastatic Prostate Cancer | 2026-12-31 |
| NCT04543799Oncology Institute of Southern SwitzerlandEvaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer | 2026-12-31 |
| NCT06776172University Hospital, Basel, SwitzerlandExtended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0. | 2027-02 |
Add all 8 to your calendar (.ics) → With an account.
Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this phase II study is to determine the early multiparametric magnetic resonance imaging response of the dominant intraprostatic lesion and correlate these findings with prostate specific antigen response in patients with intermediate to (very) high risk localized prostate cancer treated with online adaptive stereotactic radiotherapy without intraprostatic fiducial markers.
Background: Stereotactic body radiotherapy (SBRT) is an established standard of care treatment for localized prostate cancer. Recent pathological studies suggest the presence of a dominant intraprostatic lesion (DIL) within the prostate, which serve as a central driver of tumor aggressiveness and recurrence after treatment. Prostate-specific antigen (PSA) monitoring is the cornerstone of follow-up, though time to PSA nadir after SBRT can extend to 3 years.
Methods: This phase II observational study aims to evaluate the correlation between PSA response and early multiparametric magnetic resonance imaging (mpMRI) changes of the DIL(s) at 6- or 9-months following online adaptive SBRT for intermediate to (very) high risk localized prostate cancer. The primary outcome is the achievement of local control as assessed by mpMRI at 6 months post-SBRT or, if necessary, at 9 months post-SBRT (in case of image non complete response at 6 months). A complete imaging response is defined as the disappearance of all morphological and functional mpMRI changes of PIRADS (Prostate Imaging Reporting and Data System) ≥3 lesion(s) correlating with Gleason ≥7a pathology. No confirmatory biopsies will be conducted. The required sample size for this study will be 28 patients, assuming a complete response rate of 80% at 6 months, targeting an acceptable margin of error with 95% confidence, and a margin of error of 15%.
Patients referred to our tertiary referral centre for prostate cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multiparametric magnetic resonance imaging local control of the dominant intraprostatic lesion
To study multiparametric magnetic resonance imaging (mpMRI) local control of Prostate Imaging Reporting and Data System (PIRADS) ≥3 lesion(s) after SBRT. An image complete response is defined as disappearance of all morphological and functional PIRADS ≥3 lesion(s) correlating with Gleason ≥7a pathology in mpMRI.
Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.
Correlation of early prostate-specific antigen response with early multiparametric magnetic resonance imaging changes
To correlate early prostate-specific antigen response with early multiparametric magnetic resonance imaging changes of the PIRADS ≥3 lesion(s) correlating with Gleason ≥7a pathology
Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.
Correlation of late prostate-specific antigen response with early multiparametric magnetic resonance imaging changes
To correlate late prostate-specific antigen response with early multiparametric magnetic resonance imaging changes of the PIRADS ≥3 lesion(s) correlating with Gleason ≥7a pathology
Time frame: Yearly (up to 5 years post SBRT)
Correlation of genitourinary and gastrointestinal toxicity with early multiparametric magnetic resonance imaging changes
Correlating genitourinary and/or gastrointestinal toxicity (according to common terminology criteria for adverse events \[CTCAE\] version 5.0) with structural and/or functional changes of the prostate and/or surrounding organs on early multiparametric magnetic resonance imaging
Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.
Correlation of prostate quality of life with early multiparametric magnetic resonance imaging changes
Quality of life (according to EPIC-26) and relation to early structural and/or functional changes of the prostate and/or surrounding organs on multiparametric magnetic resonance imaging
Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.
To evaluate prostate volume change during and after adaptive prostate SBRT and to correlate to treatment toxicity.
To evaluate prostate volume change intra-treatment and after adaptive prostate SBRT and to correlate to treatment toxicity.
Time frame: Intra-treatment (within 1 week before the last fraction of SBRT) and 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.
Exploratory image analysis
Quantitative imaging features will be used to predict outcome and side effects on the different images.
Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.
Plan to share: Yes — Individual participant data that underlie the results reported in this trial after de-identification. Other documents may be shared include the study protocol.
Supporting information: Study protocol
Time frame: Beginning 9 months and ending 36 months after article publication.
Access criteria: Proposals to access study data should send request to matthias.guckenberger@usz.ch. To gain access, data requesters must sign data access agreement.
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Oct 2026, 26 months.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's 26 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.